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Figure 1 Enrollment and F
MR ¼ mitral valve regurgitation.
Abbreviations
and Acronyms
LVEF = left ventricular
ejection fraction
LVIDd = left ventricular
internal diameter diastolic
MR = mitral regurgitation
NYHA = New York Heart
Association
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318Surgical treatment of mitral reg-
urgitation (MR) is recommended
for patients who are symptomatic
from 3þ or 4þ MR or have evi-
dence of left ventricular dysfunc-
tion or enlargement to avoid
progressive deterioration in car-
diac function (1–3). The dura-
bility of surgicalmitral valve repair
has been studied in several single-center series (4,5). Although mitral valve regurgitation may
recur within the ﬁrst 6 months after surgical repair, the grade
of MR as ascertained by routine clinical echocardiography
generally remains stable beyond the ﬁrst year of follow-up (5).
A novel percutaneous device has been developed to reduce
MR by approximating the 2 leaﬂets of the valve (MitraClip,
Abbott, Menlo Park, California). This is the ﬁrst percuta-
neous device for MR to be compared in a randomized trial
to conventional mitral valve surgery. Percutaneous treatment
of MR with the MitraClip device is currently allowed under
CE Mark in Europe and is investigational in the United
States and parts of Asia.
The EVEREST (Endovascular Valve Edge-to-Edge
Repair Study) II randomized trial compared treatmentollow-Up in the Intention-to-Treat Groupwith the MitraClip device to treatment with surgery for MR
(6,7). At 1 year, rates of death were similar, but the rate and
degree of MR was higher with the percutaneous approach
compared with surgery. Major adverse events at 30 days were
lower overall for percutaneously treated subjects, and certain
patient groups, such as the elderly and subjects lacking
intrinsic leaﬂet pathology (e.g., with functional MR),
experienced effectiveness of the percutaneous treatment that
was comparable to surgery at 1 year in exploratory analysis.
The EVEREST II randomized trial pre-speciﬁed
mandatory clinical and echocardiographic follow-up at
1-year intervals for 5 years in both study arms, and echo-
cardiographic images were reviewed and adjudicated by
a central core laboratory. All randomized subjects reached
eligibility for 4-year follow-up at the time of this report. We
sought to compare the clinical and echocardiographic
durability of percutaneous treatment with surgical treatment
of mitral valve regurgitation at 4 years among patients
enrolled in the EVEREST II randomized trial.Methods
Patients. The EVEREST II trial is a prospective, multi-
center, randomized, nonblinded evaluation of the MitraClip
Table 1 Baseline Characteristics
Characteristic*
Percutaneous
Repair Group
(n ¼ 184)
Surgical Group
(n ¼ 95)
Age, yrs, mean  SD (n) 67.3  12.8 (184) 65.7  12.9 (95)
Sex
Male 62.5% (115/184) 66.3% (63/95)
Female 37.5% (69/184) 33.7% (32/95)
Comorbidities
Congestive heart failure 90.8% (167/184) 77.9% (74/95)
Atrial ﬁbrillation 33.7% (59/175) 39.3% (35/89)
Coronary artery disease 47.0% (86/183) 46.3% (44/95)
Prior myocardial infarction 21.9% (40/183) 21.3% (20/94)
Previous CABG 20.7% (38/184) 18.9% (18/95)
Previous percutaneous
intervention
24.0% (44/183) 15.8% (15/95)
Hypercholesterolemia 61.0% (111/182) 62.8% (59/94)
Hypertension 72.3% (133/184) 78.9% (75/95)
Diabetes mellitus 7.6% (14/184) 10.5% (10/95)
Chronic pulmonary disease 14.8% (27/183) 14.8% (14/95)
LVEF, % 60.0  10.1 (182) 60.6  11.0 (95)
NYHA functional class, % (n/N)
I 9.2% (17/184) 20.0% (19/95)
II 39.7% (73/184) 32.6% (31/95)
III 44.6% (82/184) 43.2% (41/95)
IV 6.5% (12/184) 4.2% (4/95)
MR, % (n/N)
1þ to 2þ, mild-to-moderate 0.0% (0/184) 1.1% (1/95)
2þ, moderate 4.3% (8/184) 6.3% (6/95)
3þ, moderate-to-severe 70.7% (130/184) 70.5% (67/95)
4þ, severe 25.0% (46/184) 22.1% (21/95)
Regurgitant volume, ml/beat 42.0  23.3 (174) 45.2  26.6 (88)
Regurgitant oriﬁce area, cm2 0.56  0.38 (171) 0.59  0.35 (87)
MR etiology, % (n/N)
Functional 26.6% (49/184) 27.4% (26/95)
Degenerative
With anterior or bileaﬂet ﬂail,
or prolapse
31.5% (58/184) 26.3% (25/95)
With posterior ﬂail or
prolapse
39.1% (72/184) 44.2% (42/95)
With neither ﬂail nor prolapse 2.7% (5/184) 2.1% (2/95)
*Continuous variables are mean  SD.
CABG ¼ coronary artery bypass graft surgery; LVEF ¼ left ventricular ejection fraction;
NYHA ¼ New York Heart Association; MR ¼ mitral regurgitation.
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319System in the treatment of MR. The MitraClip device,
procedure, study design, and 1-year primary endpoint
analysis have been previously described (6,7). From
September 2005 through November 2008, 279 patients were
recruited at 37 study centers in North America. Patients
were eligible for the EVEREST II trial if they had grade
3þ or 4þ chronic MR, were symptomatic with a left
ventricular ejection fraction (LVEF) of more than 25%, and
a left ventricular end-systolic diameter of 55 mm or less; or
if asymptomatic, had at least 1 of the following: an LVEF
of 25% to 60%, a left ventricular end-systolic diameter of
40 mm to 55 mm, new atrial ﬁbrillation, or pulmonary
hypertension. All eligible patients were candidates for mitral
valve repair or replacement surgery and cardiopulmonary
bypass. Patients underwent transthoracic and transeso-
phageal echocardiography to quantify mitral valve regurgi-
tation and to judge morphologic suitability for MitraClip
implantation. Pertinent exclusion criteria were a baseline
mitral valve area <4.0 cm2, presence of severe leaﬂet or
annular calciﬁcation, ﬂail width 15 mm, ﬂail gap 10 mm,
and in patients with functional etiology, a coaptation depth>11
mm below the annulus or a coaptation length <2 mm.
Before randomization, all patients provided written informed
consent for 5 years of follow-up. The study protocol was
reviewed and approved by the institutional review board of
each participating site.
Procedure. The MitraClip system is a catheter-based
device designed to approximate the mitral valve leaﬂets
while the heart is beating. The procedure is performed in
the cardiac catheterization laboratory with echocardio-
graphic and ﬂuoroscopic guidance while the patient is
under general anesthesia. The MitraClip System includes
a MitraClip device, a steerable guide catheter and a
MitraClip delivery system. The MitraClip device is
a polyester-covered mechanical device with 2 arms that are
opened and closed by control mechanisms on the delivery
catheter. The tip of the outer guide catheter is delivered
to the left atrium through a transseptal approach over
a guidewire and dilator. The MitraClip delivery system is
advanced through the guide catheter into the left atrium
and positioned so that the device is orthogonal to the
plane of the mitral valve annulus and at the origin of
the regurgitant jet. After adequacy of the grasp is assessed,
the reduction of MR is conﬁrmed, and the diastolic
transmitral gradients are assessed with the use of trans-
thoracic echocardiography, the MitraClip device is de-
ployed. If reduction in MR is inadequate with 1 device
the device may be removed or a second device placed.
Patients were treated with heparin during the procedure,
with aspirin (at a dose of 325 mg daily) for 6 months and
with clopidogrel (at a dose of 75 mg daily) for 30 days
after the procedure.
Statistical analysis. The trial primary effectiveness end-
point was freedom from death, surgery for mitral valve
dysfunction, and 3þ and 4þMR at 12 months (determined
by an echocardiographic core laboratory; Dr. Foster,University of California, San Francisco), designed to com-
pare the percutaneous treatment to surgery and demonstrate
effectiveness within a pre-speciﬁed margin of difference, and
for safety, a composite of major adverse events within
30 days, to demonstrate improvement by a pre-speciﬁed
margin. Results of analyses on this endpoint for the
intention-to-treat analysis set (entire randomized cohort)
and per-protocol cohort (subset of randomized cohort with
discharge MR 2þ) have been previously reported (7).
The endpoints to be compared between randomized
treatment groups here include the following endpoints
evaluated through 4 years (48 months) after randomized
procedure: 1) freedom from death, surgery for mitral valve
dysfunction, and 3þ and 4þMR at 48 months; 2) freedom
from surgery for mitral valve dysfunction; and 3) freedom
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320from death. Analysis of annual outcomes was pre-speciﬁed,
albeit with no adjustment for multiple testing, or plan to
compare with the original pre-speciﬁed differences com-
pared at the primary endpoint time. All of the analyses in-
cluded here, therefore, should be considered secondary.
The rate of clinical success and its components at
48 months is compared between treatments using the chi-
square continuity corrected test. In addition, Kaplan-
Meier curves of freedom from surgery and freedom from
death are presented for each treatment, with treatment
comparisons performed using the log-rank test. Patients not
experiencing the endpoint before 48 months are censored at
48 months or last known follow-up, whichever is earlier.
The analysis is performed on an intent-to-treat basis (all
randomized patients). Randomized patients who did not
receive treatment in either arm (n ¼ 21) and did not have
subsequent MR assessment were considered to maintain the
same grade of MR as baseline for the effectiveness analysis.
Analysis of the subset of patients with available 4-year data
was also performed (Online Appendix). Randomized patients
with grade 3þ or 4þ MR after the assigned percutaneous
procedure were referred for elective valve surgery and were
analyzed according to the randomized treatment arm.
Treatment comparison on demographic binary variables
was performed using Fisher’s exact test, and on demographic
continuous variables, was performed using the Student
t test. Changes from baseline on echocardiographic assess-
ment were compared among patients who completed both
the baseline and follow-up echocardiographic assessment. A
modiﬁed ridit analysis was used to compare the ordinal
categorical variables of MR grade and New York Heart
Association (NYHA) functional class (8,9).
To evaluate for heterogeneity of the treatment effect on
the composite effectiveness endpoint at 4 years, we per-
formed limited tests for interaction with treatment on those
groups where heterogeneity was observed on the 12-month
primary endpoint: age 70 years and functional versus
degenerative MR. Degenerative MR was deﬁned as the
presence of leaﬂet pathology (either anterior, or posterior or
both), and functional MR was deﬁned as the absence of
leaﬂet pathology.
All statistical analyses were performed using PC SAS for
Windows version 9.1 or higher (SAS Institute, Cary, North
Carolina).
Role of the funding source. The trial was designed by the
sponsor, Abbott Vascular, in collaboration with the inves-
tigators. Harvard Clinical Research Institute was contracted
by Abbott Vascular to perform data management, analysis,
and clinical events adjudication. All authors had access to all
data. The trial’s publication committee had ﬁnal responsi-
bility to submit the manuscript for publication.Ta
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Patients. Disposition of patients in the intention-to-treat
group is presented in Figure 1. A total of 279 patients
Table 3 Effectiveness Endpoint and Components at 4 Years
1 Year 4 Years
Percutaneous Repair Surgical p Value Percutaneous Repair Surgical p Value
Freedom from death, MV surgery
or reoperation, and MR 3þ or 4þ
55.2% (100/181) 73.0% (65/89) 0.007 39.8% (64/161) 53.4% (39/73) 0.070
Death 6.1% (11/181) 5.6% (5/89) 1.000 17.4% (28/161) 17.8% (13/73) 0.914
MV surgery or reoperation 20.4% (37/181) 2.2% (2/89) <0.001 24.8% (40/161) 5.5% (4/73) <0.001
MR 3þ or 4þ at follow-up 21.0% (38/181) 20.2% (18/89) 1.000 21.7% (35/161) 24.7% (18/73) 0.745
MV ¼ mitral valve; MR ¼ mitral regurgitation.
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321were randomly assigned in a 2:1 ratio to undergo either
percutaneous mitral valve repair (184 patients) or mitral
valve surgery (95 patients). Twenty-one patients (6Figure 2 MR Severity by Echocardiography at Baseline, 1-Year, and
(A) Mitral valve regurgitation (MR) severity at baseline and 12 months. (B) MR severity at
are presented for patients who had both baseline mitral valve regurgitation (MR) and the
indicates 1þ; light yellow indicates 2þ; dark yellow indicates 3þ; and orange indicatesrandomized to the percutaneous repair arm and 15 to
surgery) withdrew consent and did not undergo treatment
per their randomized assignment. The last patient was4-Year Follow-Up
baseline and 48 months. Results are matched for each timepoint, and comparisons
given follow-up MR. Mitral regurgitation severity: dark blue indicates 0þ; turquoise
4þ.
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322enrolled and randomized on September 17, 2008, and the
last patient was treated on November 11, 2008. The last 4-
year follow-up visit was completed on May 9, 2012. Four-
year clinical follow-up was complete in 88% in the device
group and 77% in the surgical group. The baseline charac-
teristics of patients in the 2 groups, shown in Table 1, were
generally well balanced with the exception of a history of
congestive heart failure, which was more common in the
percutaneous-repair group. Ninety patients (50.6%) were
treated with 1 MitraClip device and 68 patients (38.2%)
received 2 devices during the index procedure.
Device safety. As previously reported (7), within the ﬁrst
12 months, 9 patients were noted to have attachment of theFigure 3 Kaplan-Meier Estimates of Freedom From Death and From
(A) Kaplan-Meier estimates of freedom from death at 4 years.device to a single (rather than both) mitral valve leaﬂet.
After 12 months, 1 additional patient was noted to have
attachment of the device to a single leaﬂet. There were no
embolizations of any devices observed and all patients with
attachment of the device to a single leaﬂet were treated with
mitral valve surgery (5 replacement, 5 repair). There was no
difference in the mean change in mitral valve area by
pressure-half time or planimetry, nor in the mean change
in mitral valve gradient from baseline to 4 years (Table 2).
At 4 years, there was 1 (0.6%) case of mitral stenosis
(deﬁned as mitral valve area <1.5 cm2) in a subject with
device implanted. At discharge, this patient’s mitral valve
area and mean gradient were 1.5 cm2 and 14.5 mm Hg,Surgery at 4 Years
JACC Vol. 62, No. 4, 2013 Mauri et al.
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323respectively; and 2.0 cm2, and 14.7 mm Hg, respectively, at
30-day follow-up. The patient underwent mitral valve
replacement surgery for recurrent MR 61 days after the
index procedure.
Effectiveness endpoint at 4 years. The overall rate of
freedom from death, surgery for mitral valve dysfunction
(other than the assigned treatment in the surgical arm), and
MR 3þ or 4þ was 39.8% in the percutaneous arm versus
53.4% in the surgical arm (p ¼ 0.070) (Table 3).
Severity of mitral regurgitation. The MR severity as
measured by the echocardiography core laboratory is shownFigure 3 Continued
(B) Kaplan-Meier estimates of freedom from surgery to treat mitral valve dysfunction at 4 ye
the surgery arm, only reoperation is considered. Blue lines indicate device group (n ¼ 17for the percutaneous repair and surgical groups in Figure 2.
Both groups show an immediate reduction in the number
of patients with moderate-to-severe (3þ) and severe (4þ)
MR at discharge. Patients in the surgical group experienced
more MR reduction at discharge and throughout 4-year
follow-up than percutaneous repair group patients. At 12
months and 4 years, the proportions of patients with 3þ or
4þMR in the percutaneous repair group were 18.8% (28 of
149) and 20.6% (20 of 97), respectively (4 subjects with 3þ
or 4þ MR at year 1 died before year 4; 2 had surgery for
MR; and 7 were observed to have had a reduction in MR toars. In the percutaneous repair arm, any surgery after randomization is considered; in
8); red lines indicate control group (n ¼ 80). CI ¼ conﬁdence interval.
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3241 or 2þ; 7 were not available for follow-up; and 11 new
patients had MR 3þ). In the surgical group the proportions
of patients with 3þ or 4þMR were 3% (2 of 67) and 9.1%
(4 of 44) at 12 months and 4 years, respectively (1 patient
had a reduction in MR to 1 or 2þ and 3 new patients had
MR 3þ). The proportion of patients with 2þ or greater
MR at 12 months and 4 years were 57.1% (85 of 149) and
57.7% (56 of 97), respectively, for the percutaneous repair
group, and 23.9% (16 of 67) and 18.2% (8 of 44) for the
surgical group, respectively.
Second MitraClip procedure. Five patients in the percu-
taneous repair group underwent a second intervention to
place a second MitraClip device through 12 months. In 4 of
the 5 second MitraClip interventions, a second MitraClip
device was successfully implanted. The patient who did not
have a successful second intervention had an additional
intervention to place a second MitraClip device between
12 months and 4 years of follow-up.
Four-year mortality. Overall, 82.6% (133 of 161) of
patients in the percutaneous repair group and 82.2% (60 of
73) of patients in the surgical group were alive at 48 months
(Table 3, Fig. 3A).
Surgery for mitral regurgitation. The rates of surgery for
valvular dysfunction were 20.4% versus 2.2% at 1 year
(p < 0.001) and 24.8% versus 5.5%% (p < 0.001) overall
over 4 years in the percutaneous versus surgical groups,
respectively (Table 3, Fig. 3B). In the percutaneous repair
group, the majority of mitral valve surgery (20 repair and
17 replacement) occurred before 12 months (Fig. 3B).Table 4 Left Ventricular Dimensions by Echocardiography at Baselin
Measure Device Group Control G
Baseline
LVEDV, ml 159.03  37.33 (144) 160.39  4
LVIDd, cm 5.53  0.64 (148) 5.41  0
LVESV, ml 63.03  23.54 (144) 61.34  2
LVIDs, cm 3.62  0.88 (146) 3.31  0
Month 12
LVEDV, ml 133.71  35.52 (144) 120.19  4
LVIDd, cm 5.10  0.67 (148) 4.80  0
LVESV, ml 57.54  24.04 (144) 55.74  3
LVIDs, cm 3.53  0.83 (146) 3.29  0
Baseline*
LVEDV, ml 155.76  33.67 (94) 162.80  5
LVIDd, cm 5.51  0.59 (94) 5.40  0
LVIDd, cm 5.51  0.59 (94) 5.40  0
LVIDs, cm 3.58  0.83 (94) 3.28  0
Month 48
LVEDV, ml 125.90  33.42 (94) 113.50  4
LVIDd, cm 5.25  0.65 (94) 4.84  0
LVESV, ml 54.46  24.20 (94) 48.93  2
LVIDs, cm 3.56  0.92 (94) 3.28  0
Values are mean  SD (n). Results are matched for each time point, and comparisons are presente
given follow-up. *Among subjects with 48-month echocardiographic follow-up.
CI ¼ conﬁdence interval; LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left ventricular e
internal diameter systolic.After 1 year, 3 patients underwent mitral valve surgery;
all undergoing repair rather than replacement. In the
surgical group, 2 patients underwent reoperation through
12 months (replacement), and 2 patients underwent
reoperation (replacement) between 1 and 4 years.
Change in left ventricular dimensions. In both groups,
improvements in left ventricular end-diastolic volume, left
ventricular internal diameter, diastolic (LVIDd), and left
ventricular end-systolic volume were observed at 1 year
and were sustained at 4 years (Table 4). Left ventricular
dimensions were similar in both groups except for smaller
LVIDd in the surgical group compared with the percutaneous
repair group at 4 years (4.84 0.67 cm versus 5.25 0.65 cm,
p < 0.001).
NYHA functional class. Both groups showed an im-
provement in NYHA functional class from baseline to
12 months, which was sustained at 4 years (Fig. 4). The
proportion of patients in NYHA functional class III or IV in
the percutaneous repair group decreased from 45.7% at
baseline to 2% at 12 months, and remained low (5.7%) at
4 years. The surgical group also showed improvement in
NYHA functional class, with the proportion of patients in
NYHA functional class III or IV reduced from 44.8% at
baseline to 13.4% at 12 months, and to 6.3% at 4 years.
Interaction and subgroup analysis. Tests of interaction on
age and etiology, both signiﬁcant at 12 months, were per-
formed on the 4-year efﬁcacy endpoint. At 4 years, both
etiology and age were still signiﬁcant (p ¼ 0.023 and
p ¼ 0.025, respectively) (Fig. 5). Among 66 patients withe and 1-Year and 4-Year Follow-Up
roup
Difference
(Device-Control)
95% 2-Sided CI
p Value
2-Sided
6.66 (66) 1.35 (13.22 to 10.51) 0.836
.70 (67) 0.12 (0.07 to 0.31) 0.215
7.88 (66) 1.68 (5.64 to 9.00) 0.651
.72 (67) 0.31 (0.07 to 0.55) 0.012
4.33 (66) 13.51 (2.24 to 24.79) 0.032
.69 (67) 0.30 (0.10 to 0.50) 0.003
1.39 (66) 1.80 (5.98 to 9.58) 0.680
.80 (67) 0.23 (0.01 to 0.47) 0.056
0.82 (41) 7.04 (21.71 to 7.62) 0.420
.76 (43) 0.11 (0.13 to 0.34) 0.412
.76 (43) 0.11 (0.13 to 0.34) 0.412
.70 (43) 0.30 (0.02 to 0.59) 0.039
1.67 (41) 12.40 (0.96 to 25.76) 0.069
.67 (43) 0.41 (0.17 to 0.65) <0.001
7.89 (41) 5.52 (3.87 to 14.91) 0.247
.86 (43) 0.27 (0.06 to 0.60) 0.103
d for patients who had echocardiographic left ventricular measures both at baseline and at the
nd-systolic volume; LVIDd ¼ left ventricular internal diameter diastolic; LVIDs ¼ left ventricular
Figure 4 NYHA Functional Class at Baseline and 1-Year and 4-Year Follow-Up
(A) New York Heart Association (NYHA) functional class at baseline and 12 months. (B) NYHA functional class at baseline and 48 months. Results are matched for each
timepoint, and comparisons are presented for patients who had both baseline mitral valve regurgitation (MR) and the given follow-up MR. Dark blue indicates NYHA functional
class I; turquoise indicates class II; yellow indicates class III; and orange indicates class IV.
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325functional MR, the efﬁcacy endpoint rate at 4 years was
34.1% versus 22.7% in the percutaneous repair and surgical
groups, respectively (p ¼ 0.344). Of subjects with 3þ or 4þ
MR at 4 years, functional MR was more prevalent in the
surgical arm (9 of 22 subjects) than in the percutaneous arm
(8 of 44 subjects).
Discussion
Percutaneous treatment of MR with the MitraClip device
was compared with surgery in the EVEREST II random-
ized trial, and the follow-up of these subjects to 4 years was
studied to determine the durability of this procedure to
4 years. Although patients treated with percutaneoustherapy achieve less complete reduction in MR at discharge
and at 1 years as measured by echocardiography, we found
that after year 1, few patients in either treatment arm had
recurrent MR or required a repeat mitral valve procedure
between years 1 and 4, and mortality rates were not different
between the treatment arms at 1 year or 4 years. For the
overall trial population, beneﬁts in terms of reduction in
NYHA class were sustained and comparable to surgery.
Although left ventricular dimensions were reduced with
either therapy, the degree of reduction was greater for
surgery. In the subset of patients with functional MR, who
appeared to have had comparable outcomes with the
percutaneous procedure compared with surgery at 1 year,
these results were sustained, as measured by freedom from
Figure 5 Subgroup Analyses of Efﬁcacy Endpoint at 4 Years
Shown are the differences in rates of the efﬁcacy endpoint (freedom from death, from mitral valve surgery, and from grade 3þ or 4þ mitral regurgitation [MR]) between patients
in the percutaneous repair group and patients in the surgery group for all patients and for those in 2 subgroups (age and MR etiology). CI ¼ conﬁdence interval.
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326death, operation for mitral valve dysfunction, or recurrent
MR of grade 3þ or higher.
Percutaneous treatment of MR with the MitraClip device
is currently allowed under CE Mark in Europe and is
investigational in the United States. The observation that
the results of percutaneous treatment are sustained between
1 and 4 years in this study is of critical importance when
considering this novel approach. Although there was an up-
front lower procedural success rate with percutaneous
therapy in the overall trial population, if the percutaneous
approach was initially successful, the results were durable,
without evidence of late device complications. It is impor-
tant to consider that the level of procedure experience both
by individual operators and overall as well in the EVEREST
II trial represents early experience with this novel device.
Ten patients (5%) had single leaﬂet device attachment in
this trial, whereas the rate of single leaﬂet device attachment
in practice now is closer to 1% (10). Furthermore, placement
of a second device has become more frequent in use of this
device after this trial. Therefore, the acute results of this trial
of a novel treatment represent early experience that is already
being reﬁned in clinical trials and practice.
Almost all of the MitraClip-treated patients who require
an additional procedure do so within the ﬁrst 6 months after
initial treatment (Fig. 3B). After this, the rates of reopera-
tion or additional MitraClip procedures are no different
between the 2 treatment groups. Based on prior experiencewith mitral valve surgical repair, there was a concern that the
greater amount of post-procedural residual MR in the
MitraClip group would lead to more subsequent cross-over
to surgery as time passed, or that lesser degrees of residual
MR (2þ) would result in later deterioration of the 1-year
results. Although there does not appear to be signiﬁcant
change in MR grade ventricular function or dimension in
follow-up, longer-term follow-up of the subset of patients
with MR 2þ is ongoing.
The stability of the results in MitraClip-treated patients
up to 4 years is a key ﬁnding of this report, with preserved
left ventricular function, and ventricular dimensions in
follow-up, and few additional patients having increased MR
grade after the ﬁrst year of follow-up. The ﬁnding that some
patients with MR3þ at 1 year were measured to have 2þ at
4 years, and vice versa, suggests that there is variability in
MR or in the measurement of MR over time. This vari-
ability may be explained by changing hemodynamic condi-
tions or by left ventricular or valvular remodeling within
individual subjects. While such variability is expected of
a categorical endpoint, we sought to minimize this by the
use of standardized criteria employed by an echocardio-
graphic core laboratory. The results in the surgical arm
showed that mitral regurgitation was not unusual in follow-up,
and these rates were somewhat higher than those reported in
single-center series. It is likely that this observation results
from the presence of an echocardiographic core laboratory as
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327well as from the trial including relatively older patients with
more frequent functional MR than those reported in
national databases. While the trial inclusion criteria were
broad, it is possible that such patients and their physicians
were more likely to seek out a percutaneous option even
within the context of a randomized trial.
Current experience outside of the United States has
shown that percutaneous therapy for MR tends to be
selected for patients with either functional MR, and/or
patients with higher than average surgical risk (11). Because
of the complex pathophysiological underpinnings of ven-
tricular dysfunction and concurrent coronary artery disease,
patients with functional MR represent a treatment chal-
lenge where surgical treatment options are more limited
than for those with isolated leaﬂet pathology, and are
associated with more residual or recurrent MR. In these
patients, the relative beneﬁt of surgery over medical ther-
apy is less clear (1–3). While the EVEREST trial was
designed to compare a broad spectrum of patients with
MRdincluding both degenerative and functional etiologies
of MRdpatients with degenerative MR appeared to derive
greater beneﬁt from surgery relative to the percutaneous
procedure compared with patients with functional MR,
a population with more difﬁculty avoiding recurrent MR
after surgery (12). Moreover, patients with degenerative
MR who are at high risk for surgery might be expected to
have improvements in clinical status with percutaneous
repair even if MR reduction is less complete than would
have been surgery.
The ﬁndings we describe should be viewed in the context
of the study design. We chose to utilize an intention-to-treat
comparison, following the standard reporting of comparison
of treatment strategies, even though some patients, more
commonly in the surgical arm, did not receive the assigned
therapy. An analysis of patients as treated has shown
consistent results regarding 1-year to 4-year durability of
ﬁndings, and within the subgroup of subjects with functional
MR. While 5-year follow-up was speciﬁed in the patient
consent, many patients withdrew or were lost to follow-up
before the 4-year visit, and this was more common in the
surgical arm. To overcome this, we performed analysis of
MR grade assuming that the last available MR grade was
carried forward. However, results using only available data
show a lower rate of MR 3þ or 4þ at 4 years in the surgical
arm than in the imputed data, and lower than the percuta-
neous arm. While the results of the imputed data may be
biased toward the null, the results for the available data
are likely biased toward follow-up of those with more
favorable outcomes. Furthermore, the ﬁndings in the
subgroup with functional MR, even with a positive test for
interaction, should be viewed as exploratory. Given the
overall sample size, further categorizing subgroups according
to components of the primary endpoint or secondary
endpoints is limited by power and multiple testing. Whether
these results will be reproducible is the subject of 2 ongo-
ing randomized trials in Europe and the United States,comparing percutaneous treatment with the MitraClip
device to surgical therapy in patients with functional MR.
Finally, while it is reassuring that there is no associated
increase in mortality with a percutaneous strategy despite
less effective reduction in mitral regurgitation, the sample
size and relatively low mortality rate precludes sufﬁcient
power to fully understand the impact of the degree of
reduction of mitral regurgitation on long-term survival in
operative candidates.
Conclusions
At 4 years, surgery remains the standard of care for treat-
ment of MR among eligible patients. Percutaneous repair
is associated with similar mortality and symptomatic
improvement but a higher rate of MR requiring repeat
procedures, and less improvement in left ventricular
dimensions than surgery. Although percutaneous repair of
the mitral valve to treat MR was associated with a higher
rate of residual MR at 1 year, there was no difference in later
occurrence of MR or mitral valve intervention between
1-year and 4-year follow-up. Further studies are necessary in
patients with functional MR where percutaneous treatment
was most comparable to surgery in terms of late efﬁcacy.
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